{"id":1544,"date":"2026-11-16T14:14:30","date_gmt":"2026-11-16T14:14:30","guid":{"rendered":"https:\/\/admit-therapeutics.com\/?p=1544"},"modified":"2026-11-16T14:29:07","modified_gmt":"2026-11-16T14:29:07","slug":"we-are-at-medica-2026-presenting-map-ad-our-prognostic-test-for-alzheimers-dementia","status":"publish","type":"post","link":"https:\/\/admit-therapeutics.com\/en\/we-are-at-medica-2026-presenting-map-ad-our-prognostic-test-for-alzheimers-dementia\/","title":{"rendered":"We are at MEDICA 2026 presenting MAP-AD\u00ae, our prognostic test for Alzheimer&#8217;s Dementia"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Barcelona (Spain), November 16, 2026. We are already present at\u00a0<strong>MEDICA2026<\/strong>, the leading international event for the medical and healthcare technology sector. Throughout the exhibition, our team is welcoming professionals and strategic partners at\u00a0<strong>Hall 1, Booth D33<\/strong>\u00a0to present the\u00a0<strong>MAP-AD\u00ae<\/strong>\u00a0test in detail.<br><br>MAP-AD\u00ae is a CE-IVDR marked prognostic blood test designed to predict the progression of Mild Cognitive Impairment (MCI) to Alzheimer&#8217;s dementia. To achieve this, it combines the analysis of novel mitochondrial epigenetic biomarkers with the patient&#8217;s clinical data using a machine-learning approach.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Anticipating progression for better clinical management<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Thanks to this integration of molecular biology and artificial intelligence, MAP-AD\u00ae helps medical professionals anticipate clinical progression, enabling earlier, more precise, and informed patient management.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Come meet us at Hall 1, Booth D33<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">If you are visiting the exhibition, stop by our booth to discover the capabilities of our test firsthand. Our International Business Developer, Lee Creaser, is available at the event to meet with you and discuss how we can bring precision prognosis to your laboratory or healthcare network.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"767\" height=\"1024\" src=\"https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2026\/11\/PostLinkedin_Medica26-767x1024.png\" alt=\"\" class=\"wp-image-1547\" srcset=\"https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2026\/11\/PostLinkedin_Medica26-767x1024.png 767w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2026\/11\/PostLinkedin_Medica26-225x300.png 225w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2026\/11\/PostLinkedin_Medica26-768x1025.png 768w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2026\/11\/PostLinkedin_Medica26-1150x1536.png 1150w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2026\/11\/PostLinkedin_Medica26-1534x2048.png 1534w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2026\/11\/PostLinkedin_Medica26-scaled.png 1917w\" sizes=\"auto, (max-width: 767px) 100vw, 767px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Barcelona (Spain), November 16, 2026. We are already present at\u00a0MEDICA2026, the leading international event for the medical and healthcare technology sector. Throughout the exhibition, our team is welcoming professionals and strategic partners at\u00a0Hall 1, Booth D33\u00a0to present the\u00a0MAP-AD\u00ae\u00a0test in detail. MAP-AD\u00ae is a CE-IVDR marked prognostic blood test designed to predict the progression of Mild [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1544","post","type-post","status-publish","format-standard","hentry","category-sin-categorizar"],"acf":[],"_links":{"self":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts\/1544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/comments?post=1544"}],"version-history":[{"count":3,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts\/1544\/revisions"}],"predecessor-version":[{"id":1555,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts\/1544\/revisions\/1555"}],"wp:attachment":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/media?parent=1544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/categories?post=1544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/tags?post=1544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}